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DNA gyrase, a typical type II topoisomerase that can introduce negative supercoils in DNA, is essential for
replication and transcription in prokaryotes. The apicomplexan parasite Plasmodium falciparum contains the
genes for both gyrase A and gyrase B in its genome. Due to the large sizes of both proteins and the unusual
codon usage of the highly AT-rich P. falciparum gyrA (PfgyrA) and PfgyrB genes, it has so far been impossible
to characterize these proteins, which could be excellent drug targets. Here, we report the cloning, expression,
and functional characterization of full-length PfGyrB and functional domains of PfGyrA. Unlike Escherichia
coli GyrB, PfGyrB shows strong intrinsic ATPase activity and follows a linear pattern of ATP hydrolysis
characteristic of dimer formation in the absence of ATP analogues. These unique features have not been
reported for any known gyrase so far. The PfgyrB gene complemented the E. coli gyrase temperature-sensitive
strain, and, together with the N-terminal domain of PfGyrA, it showed typical DNA cleavage activity. Further-
more, PfGyrA contains a unique leucine heptad repeat that might be responsible for dimerization. These
results confirm the presence of DNA gyrase in eukaryotes and confer great potential for drug development and
organelle DNA replication in the deadliest human malarial parasite, P. falciparum.
DNA topoisomerases are a special class of enzymes that
promote the interconversions of various topological forms of
DNA that are generated during DNA replication, transcrip-
tion, recombination, or related processes (8, 12). These en-
zymes are grouped mainly into two classes, namely, type I and
type II, based on their ability to break one or both strands of
DNA. Type II enzymes are further divided into A and B
subclasses. The archaeon Sulfolobus shibatae contains structur-
ally distinct type IIB topoisomerases (8). Eukaryotic type IIA
topoisomerases form homodimers, whereas bacterial type IIA
enzymes form heterotetramers comprised of two subunits of A
and B polypeptides each (8).
The DNA gyrase falls into the type IIA category, and it is
responsible for catalyzing ATP-dependent DNA supercoiling
activity in prokaryotes (22, 31). The best-studied gyrase so far
is from Escherichia coli, which forms an A2B2 complex. The
GyrA N-terminal domain contains the DNA breakage and
union domain, while the C-terminal domain shows DNA wrap-
ping activity (41, 42). The GyrB N-terminal domain has an
ATPase function, whereas the C-terminal domain binds to
DNA and probably interacts with GyrA (6, 9, 21). These en-
zymes are excellent targets for various antibacterial agents
including quinolones and coumarins (1, 16, 32, 33).
Although gyrase is commonly found in prokaryotes, there
are a few recent reports of the existence of bacterium-type
gyrases in plants that might be important for organellar DNA
replication and transcription. It has been shown that Arabidopsis
thaliana DNA gyrase is targeted to the chloroplast and mi-
tochondria and that both subunits are essential for growth
(51).
Similar to Arabidopsis, the apicomplexan parasite Plasmo-
dium falciparum harbors a relict plastid or apicoplast, which
possesses a 35-kb circular genome (57, 58, 59). There is phy-
logenetic evidence to suggest that the probable origin of the
apicoplast could be due to the engulfment of photosynthetic
algae by an ancient protist (4, 18, 58). This organelle became
essential for cell survival at later stages of evolution due to its
retention of type II fatty acid, isopentenyl diphosphate, and
heme biosynthesis pathways (39). The apicoplast genome
codes only for some housekeeping genes, few tRNAs, and
rRNAs, and therefore, the replication and transcription pro-
cesses of the apicoplast genome are dependent on nuclear-
encoded apicoplast-targeted proteins (4, 20).
The nuclear genome sequence of the apicomplexan parasite
P. falciparum contains homologues of both gyrA and gyrB in
addition to topoisomerase II (4, 20). Also, the sensitivity of P.
falciparum to ciprofloxacin provided a strong clue for the pres-
ence of these enzymes in this organism. A mammalian type II
topoisomerase inhibitor could cleave both P. falciparum nu-
clear and apicoplast DNA, whereas the gyrase-specific drug
ciprofloxacin could specifically cleave apicoplast DNA without
affecting the nuclear DNA (17, 55).
Since malaria continues to be a major health problem glob-
ally, there is an urgent need to identify new targets for the
development of novel drugs and vaccines. The apparent ab-
sence of gyrases in humans and their presence in Plasmodium
falciparum make it an excellent target for a range of antibac-
terial agents. In fact, various quinolone drugs and their deriv-
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atives that are very potent against bacteria have also been
shown to disrupt P. falciparum parasites (2, 3, 10, 15). How-
ever, efforts to use gyrase inhibitors to kill the parasites have
been somewhat limited due to the nonavailability of recombi-
nant enzymes from Plasmodium falciparum to study biochem-
ical activity and screen inhibitors. There are no data regarding
the expression of these proteins in P. falciparum and their
targeting to the apicoplast, the organelle that is supposed to
harbor these enzymes. These problems could be attributed to
the fact that both P. falciparum gyr (Pfgyr) genes are relatively
large (100 kDa) and the unusual codon usage associated with
the highly AT-rich sequence of P. falciparum (80%). After
not being able express P. falciparum gyr genes due to the
above-mentioned problems, Khor et al. recently reported the
cloning and characterization of the ATP binding domain of
the P. vivax gyrB (PvgyrB) gene, which contains52% AT content
(30). The 43-kDa PvGyrB polypeptide shows ATPase activity
that can be inhibited by the drug coumermycin. According to
that study, full-length recombinant PvGyrB formed inclusion
bodies, and the refolded protein was almost inactive (30). The
high AT content of the Plasmodium falciparum genome, the
unusual codon usage, and the presence of asparagine and ly-
sine repeats within the coding region make it very difficult to
work with large proteins of this organism (37). Therefore,
more attempts to express only the functional domains of the
relevant proteins for their biochemical characterization or to
study these proteins/enzymes in related Plasmodium species
that contain normal AT content are being made. Due to these
problems, there is hardly any report in the literature of a large
Plasmodium falciparum protein (100 kDa) being purified un-
der physiological conditions. However, the challenges and
complexities of P. falciparum could not be revealed completely
by studying the functionally similar enzymes/proteins in related
Plasmodium species. Ultimately, any drug or inhibitor has to be
designed against the protein from the same species that causes
more fatal disease symptoms.
To investigate the biochemical and pharmacologic prop-
erties of Plasmodium falciparum gyrases, we took the chal-
lenge to express PfgyrA and PfgyrB genes by using a variety
of expression systems and conditions. Here, we report for
the first time the cloning, expression, and purification of
full-length PfGyrB and functional domains of PfGyrA. Un-
like E. coli GyrB (EcGyrB), PfGyrB shows intrinsic ATPase
activity and follows a linear pattern of ATP hydrolysis char-
acteristic of dimer formation in the absence of ATP ana-
logues. This suggests that the enzyme kinetics of the protein
are truly different from those of its E. coli counterpart. The
PfgyrB gene complemented the E. coli gyrase temperature-
sensitive strain, and, together with the PfGyrA N terminal
domain, it efficiently performed typical DNA cleavage ac-
tivity. Both proteins are localized in the apicoplast, as shown
by immunofluorescence assays. Furthermore, we have iden-
tified a hydrophobic core region that might be important for
ATP-independent dimerization of PfGyrB. These results
confirm the presence of DNA gyrases in P. falciparum and
suggest their role in organelle replication, which could pos-
sibly be interrupted by using novel drugs against these en-
zymes in the future.
MATERIALS AND METHODS
Parasite culture and bacterial strains. Plasmodium falciparum strain 3D7 was
cultured in human erythrocytes in RPMI 1640 medium supplemented with 0.2%
NaHCO3, 10% heat-inactivated pooled human serum type A, gentamicin sulfate
(10 g/ml), and 0.2% glucose. For synchronization of the parasites, cells were
treated with 5% sorbitol. Parasites were checked routinely under a microscope
before harvesting. To lyse the infected erythrocytes, 0.05% saponin was used, and
parasites were recovered by centrifugation (1,000  g) and washed with cold
phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4) (34).
E. coli strain DH10B was used for cloning purposes. BL21 Codon Plus and
BLR(DE3) cells were used for the expression of the recombinant proteins. E. coli
strains KNK453 [E. coli gyrA(Ts)] and N4177 [E. coli gyrB(Ts)] were used for the
complementation assay. The details of these strains are listed in Table S1 in the
supplemental material.
DNA manipulations. Plasmodium falciparum gyrA and gyrB genes were ampli-
fied by PCR using Pfu DNA polymerase (Stratagene), P. falciparum strain 3D7
genomic DNA as a template, and specific primer sets (P8 and P9 for PfgyrA and
P1 and P2 for PfgyrB) (see Table S2 in the supplemental material) (49). The
details of the cloning of the full-length and different deletion and point mutant
forms of PfgyrA, PfgyrB, and the E. coli counterparts for protein expression and
complementation studies are discussed in the supplemental material. All rele-
vant primers are shown in Table S2 in the supplemental material.
The PfACP gene was amplified by reverse transcription (RT)-PCR using the
specific primers P25 and P26 (see Table S2 in the supplemental material), cloned
into BamHI and XhoI sites of plasmid pGEX6P2, and subsequently sequenced.
RNA extraction and RT-PCR analysis. Total RNA was isolated from the
infected erythrocytes at different stages by using TRIzol reagent (Life Technol-
ogies) according to the protocol supplied by the vendor. The RT product was
made by using an Invitrogen kit according to the manufacturer’s instructions.
The RT products were subsequently used for PCR using the specific primers P11
and P12 for PfgyrA and P1 and P4 for PfgyrB. For a loading control, RT-PCR was
performed using primers P23 and P24 for PfGAPDH. All primers are shown in
Table S2 in the supplemental material.
Protein purification, raising polyclonal antibodies, and Western blot analysis.
In order to purify the fusion proteins, Escherichia coli strain BL21 Codon Plus or
BLR(DE3) was transformed with pET28a recombinant plasmid constructs. Sev-
eral conditions were optimized for the purification of wild-type and mutant forms
of PfGyr and EcGyr proteins. The details of the protein purification methods
(including glutathione S-transferase [GST]-P. falciparum acyl carrier protein
[ACP]) are described in the supplemental material.
Protein concentrations were determined by the Bradford method (Bio-Rad
kit), according to the instructions of the vendor, by using bovine serum albumin
(BSA) as a standard.
Polyclonal antibodies against purified His6-PfGyrACC (PfGyrA coiled coil
domain) and GST-PfACP were raised in mice and against His6-PfGyrBC in
rabbits using essentially the protocol described previously by Harlow and Lane
(27). All the antibodies were later purified by affinity purification.
The fraction of the anti-GST antibodies from anti-GST-PfACP serum was
separated by affinity binding to purified GST.
Western blot analysis was carried out according to standard procedures (44).
Immunofluorescence. Immunofluorescence assays using anti-PfGyrA, anti-
PfGyrB, and anti-GST-PfACP were performed essentially as described else-
where previously (34), with minor modifications.
Complementation assay. The complementarity of PfgyrA/PfgyrB with their E.
coli counterparts was tested by transforming into E. coli strains KNK453
[gyrA(Ts)] and N4177 [gyrB(Ts)] (51), the conditional lethal mutants for E. coli
gyrA/gyrB alleles, with recombinant plasmids pAD1/pAD2 and pHH3/pAG111,
respectively, or pBR322 alone followed by checking the survival of E. coli colo-
nies at nonpermissive temperatures (43°C and 42°C, respectively) in the presence
of ampicillin and a range of IPTG (isopropyl--D-thiogalactopyranoside) con-
centrations from 0.1 mM to 0.5 mM.
ATP hydrolysis assay. The assay of the ATPase activity (in a 20-l reaction
mixture volume) of PfGyrB was carried out using a solution containing super-
coiling buffer (containing 35 mM Tris-HCl [pH 7.5], 4 mM MgCl2, 24 mM KCl,
5 mM dithiothreitol [DTT], 1.8 mM spermidine, 0.36 mg/ml BSA, and 6.5%
glycerol), 1 mM ATP, 3.4 fmol of [-32P]ATP, and the required amount of
PfGyrB or other proteins as indicated in the figure legends (25). The reaction
mixtures were incubated at 25°C for 1 h, which was followed by incubation on ice
to stop the reactions. Released inorganic phosphate (Pi) was separated by thin-
layer chromatography on a polyethylenemine cellulose strip (Sigma-Aldrich)
dipped in 0.5 M LiCl and 1 M formic acid at room temperature for 1 h. The
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thin-layer chromatography plate was dried, autoradiographed, and analyzed by
using a phosphorimager (Fujifilm BAS-1800) for quantitation.
The coupled ATP hydrolysis (20-l reaction mixture) in the presence of
PfGyrB (wild type [WT]), PfGyrBN1, or EcGyrB43 was carried out in a reaction
buffer containing 10 mM Tris-acetate (pH 7.9), 5 mM potassium acetate, 2.5 mM
magnesium acetate, 2 mM DTT, and 2 mM ATP for 30 min at room tempera-
ture. The reaction was stopped by incubating the reaction mixture in a boiling
water bath for 5 min. After cooling the samples to 22°C, 130 l of a solution
containing 10 mM Tris-acetate (pH 7.9), 5 mM potassium acetate, 2.5 mM
magnesium acetate, 2 mM DTT, 0.5 mM phosphoenolpyruvate, 0.32 mM
-NADH, 9.8 units of pyruvate kinase, and 15.6 units of lactate dehydrogenase
was added. The samples were centrifuged at 10,000  g for 1 min, and the
absorbance data were collected by using a Spectramax 250 microplate spectro-
photometer equipped with SOFTmax software (Molecular Devices). The rate of
the reaction was calculated as discussed elsewhere previously (30).
The substrate-dependent coupled ATP hydrolysis reactions were carried out
as described previously (1, 45), and the absorbance data were collected by using
an Ultrospec 2100 spectrophotometer (Amersham Biosciences).
DNA cleavage and supercoiling assay. DNA cleavage assays were carried out
in a reaction buffer containing 35 mM Tris-HCl (pH 7.5), 24 mM KCl, 2 mM
CaCl2, 2 mM spermidine, 50 g/ml BSA, 6.5% glycerol, 5 mM DTT, and 1.5 mM
ATP in the presence of 10 g/ml supercoiled pBR322 DNA in a total reaction
mixture volume of 30 l. The samples were incubated at 25°C for 1 h, and the
reaction was terminated by the addition of 3 l of 2% sodium dodecyl sulfate
(SDS) and 1 l of 5 mg/ml proteinase K (Sigma). Samples were further incubated
at 37°C for 45 min and electrophoresed in a 1% agarose gel. The gel was finally
stained with ethidium bromide. In case of quinolone-induced cleavage, 2 mM
CaCl2 was replaced with 4 mM MgCl2 (41).
The supercoiling assays were carried out in the same buffer described above
for CaCl2-induced cleavage except that 4 mM MgCl2 replaced 2 mM CaCl2 and
human Topo I (Fermentas)-treated relaxed pBR322 was used in place of super-
coiled DNA (41).
Glutaraldehyde cross-linking assay, native PAGE analysis, and gel filtration
chromatography. The cross-linking reaction was performed to stabilize the
dimer/oligomer forms of the proteins, which can be distinguished from the
monomer forms following SDS-polyacrylamide gel electrophoresis (PAGE)
analysis. A typical cross-linking reaction buffer (20 l) contains phosphate-
buffered saline and glutaraldehyde at a final concentration of 0.001%. The
samples were incubated in a 37°C water bath for 15 min and boiled at 95°C for
3 min after the addition of 3 l SDS sample buffer and finally loaded onto a 10%
SDS gel and subjected to Western blot analysis by using anti-His6 antibodies
(35). In the case of PfGyrBN2 and ECGyrN, the cross-linking was carried out in
the presence or absence of coumermycin in a buffer containing 10 mM Tris-HCl,
100 mM KCl, 4 mM DTT, 4 mM MgCl2, and 0.002% glutaraldehyde. The
incubation was carried out at 25°C for 2 h. For PfGyrB (WT), incubation at 25°C
for 4 h was done in the same buffer as that for PfGyrBN2. The reactions were
terminated by the addition of 2 SDS sample buffer and boiling at 95°C for 3
min. The samples were loaded onto a 10% SDS-PAGE gel and subsequently
subjected to Western blot analysis by using anti-His6 antibodies (45). For native
PAGE analysis, one microgram of each protein, as shown in Fig. 6E, was loaded
onto a 10% native PAGE gel, and the proteins were resolved by using 1
Tris-borate-EDTA followed by Coomassie staining.
Wild-type PfGyrB, PfGyrBN1, or PfGyrBN2 was subjected to size-exclusion
chromatography on a Pharmacia Superose-12 gel filtration column in a buffer
containing 50 mM Tris-Cl (pH 7.4), 1 mM EDTA, 10 mM -mercaptoethanol,
100 M phenylmethylsulfonyl fluoride, 10% glycerol, and 100 mM NaCl. The
column was previously calibrated using Pharmacia low- and high-molecular-
weight standards as indicated on the top panel of Fig. 6H. Fractions (0.5 ml) were
collected in each case. The fractions were checked for the presence of proteins
by SDS-PAGE analysis.
RESULTS
Cloning, sequence analysis, and expression of full-length
and different domains of gyrase A and gyrase B of Plasmodium
falciparum and E. coli. The Plasmodium Genomic Database
(http://www.plasmodb.org) shows the presence of two open
reading frames annotated as putative gyrA and gyrB genes
(PFL1120c and PFL1915w, respectively). The PfGyrA
polypeptide shows 57% homology at the N terminus and 45%
homology at the C terminus, whereas the identity is 38% at the
N terminus and 24% at the C terminus when compared to
EcGyrA. PfGyrB overall shows 41% homology and 28% iden-
tity overall with its E. coli counterpart. Both polypeptides con-
tain N-terminal extensions (165 and 120 amino acids, re-
spectively) that do not show any homology with the E. coli
gyrases. Later, using PlasmoAP and PATS prediction pro-
grams, it was found that these N-terminal sequences contain an
apicoplast-targeting sequence that includes both the transit
peptide as well as the signal peptide (19, 39, 40). It is likely that
these enzymes are associated with the 35-kb plastid DNA rep-
lication or transcription. Putative plastid-targeting elements
have been identified in the Arabidopsis thaliana gyrase genes
(51). Transit and signal peptides might interfere with the ex-
pression and purification of these proteins from bacteria (54).
Therefore, in order to clone PfgyrA and PfgyrB genes, PCRs
were performed using 3D7 genomic DNA and specific primers
(as shown in Table S2 in the supplemental material), excluding
the region that contains the apicoplast-targeting sequence.
Following PCR, 2.6-kb and 3.1-kb products were obtained
for PfgyrB and PfgyrA genes, respectively, as shown in Fig. 1A.
The PCR products were subsequently cloned into vector
pET28a and sequenced completely by using overlapping prim-
ers. The deduced sequences perfectly matched the sequences
reported in the database (see Fig. S1A and B in the supple-
mental material). The various functional domains of PfGyrA
and PfGyrB are represented in the schematic diagrams (thin
blocs) shown in Fig. 1B and C. The extreme N terminus of
PfGyrA contains a signal peptide followed by the Topo IV
domain responsible for DNA breakage and reunion. There is a
unique region at the C-terminal domain that contains leucine
heptad repeats that overlaps with the coiled-coil domain. This
region could be involved in the dimerization of PfgyrA. This
region also contains a conserved GyrA C-terminal region. In-
terestingly, the functional C- and N-terminal domains are sep-
arated by low-complexity repeat regions not found in any other
gyrases.
PfGyrB contains a signal peptide at the extreme N terminus
followed by a conserved ATPase domain and a gyrase B do-
main separated by a low-complexity region. The C terminus
contains a conserved TOPRIM domain. For analogy, we also
cloned and analyzed the conserved domains of E. coli gyrase A
and gyrase B subunits (Fig. 1D and E). The wild type and
several deletion mutants were generated by PCR amplification
followed by cloning in vector pET28a (Fig. 1B to D).
The expression and purification of Plasmodium proteins in
the heterologous system are difficult due to the high AT rich-
ness of the genome and the unusual codon usage. Moreover,
the situation gets worse due to the presence of asparagine and
lysine repeats within the coding region (37, 43). Therefore, we
decided to express full-length gyrase as well as different do-
mains of the gyrases excluding some of these repeats. E. coli
strain BL21 Codon Plus was transformed with all pET28a
recombinant constructs, followed by the expression and puri-
fication of these proteins as His6-tagged fusion proteins by
essentially following the protocol described in Materials and
Methods. The purified proteins were analyzed by SDS-PAGE
(Fig. 1F). We were able to express and purify full-length and
different domains of PfGyrB, EcGyrA, and EcGyrB (as shown
in Fig. 1E). Even after extensive efforts, we were unable to
express full-length PfGyrA, although we managed to express
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and purify two functional domains of PfGyrA (PfGyrAN and
PfGyrACC).
Expression of PfGyrA and PfGyrB at the transcript and pro-
tein levels. In order to find out whether PfGyrA and PfGyrB are
truly expressed at the mRNA level during the asexual erythrocytic
stages, RT-PCR analysis was performed using cDNA isolated
from various erythrocytic stages. Total RNA was extracted from
ring-, trophozoite-, and schizont-stage parasites, which was fol-
lowed by the preparation of cDNA according to protocols de-
scribed in Materials and Methods.
Analysis of the RT-PCR product revealed that PfGyrA is
expressed mostly during the trophozoite and schizont stages
(Fig. 2A). The expression of PfGyrB could be detected during
the ring stage, although the expression level peaked during
later stages. In order to rule out the possibility of genomic
DNA contamination in the cDNA, total RNA was treated with
FIG. 1. Cloning, expression, and purification of full-length and different deletion mutants of PfgyrA/B and EcgyrA/B genes. (A) PCR amplifi-
cation of PfgyrA and PfgyrB genes. The lanes from left to right show the DNA ladder and amplified PfgyrB and PfgyrA gene products, respectively.
(B to E) Schematic representation of PfGyrA, PfGyrB, EcGyrA, and EcGyrB polypeptides showing the putative functional domains. The dark
patches inside the main blocs represent low-complexity regions. The wild type and different deletion mutants of each polypeptide used in this study
are also shown along with their respective amino acid positions. (F) Purification of the wild type and deletion mutants of PfGyr/EcGyr A and B
subunits. Different proteins, as indicated at the top, were purified using Ni-nitrilotriacetic acid affinity purification and subjected to 10%
SDS-PAGE followed by Coomassie staining as described in Materials and Methods. “M” indicates molecular mass markers (in kilodaltons).
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FIG. 2. Stage-specific expression and apicoplast localization of PfGyrA/B. (A) RT-PCR analysis of PfGyrA and PfGyrB. RT-PCR products of
PfGyrA, PfGyrB, and PfGAPDH were obtained by using the cDNA templates from ring, trophozoite (TROPH.), and schizont stages of the
parasite life cycle and electrophoresed in a 1% agarose gel. RT lanes with a  indicate PCR products that were obtained by using a cDNA
template, and RT lanes with a  indicate the negative control. GAPDH was used as the loading control. (B) Changes (n-fold) in the expression
of PfGyrA, PfGyrB, and PfGAPDH at the mRNA level at different erythrocytic stages of the parasites. The relative intensity of each band was
calculated using densitometry scanning, and the absolute values were obtained by normalizing them against the background intensity. This figure
shows the averages of three independent sets of different experiments. (C) Specificities of anti-PfGyrB, anti-PfACP, and anti-PfGyrA antibodies.
The Coomassie-stained SDS-PAGE gel in the left panel shows purified His6-PfGyrBC, GST-PfACP, and His6-PfGyrACC, which were used as
immunogens to raise the antibodies in animals. In the Western blot analysis (right three panels), the respective antibodies recognized the antigens
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DNase I, and it was processed similarly to how it was done for
cDNA preparation, except for the addition of reverse tran-
scriptase enzyme (Fig. 2A). No products were obtained in these
lanes, suggesting that RT products were not contaminated with
genomic DNA. As an internal control, a specific region of
PfGAPDH was amplified using specific primers shown in Table
S2 in the supplemental material. The RT-PCR analysis was
repeated three times. For quantitation, the relative intensity of
each band from each experiment was calculated by densitom-
etry scanning, and absolute values were obtained by normaliz-
ing against the background intensity (34). After careful analysis
of these results, it was found that the expression level of con-
trol glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
fluctuates between 1 and 1.7 during the different erythrocytic
stages. The expression level of PfGyrB peaks at the trophozo-
ite stage, with a slight decrease in the schizont stage. On an
absolute scale, these values increased six to eight times at the
later stages compared to that of the ring stage (Fig. 2B). The
expression level of PfGyrA was low compared to those of
PfGyrB and GAPDH. PfGyrA expression could be detected
only during the trophozoite and schizont stages. It is interest-
ing that apicoplast DNA replication overlaps with nuclear
DNA replication (5, 28, 38, 56). Since nuclear DNA replication
takes place during the late trophozoite and schizont stages (24),
it can be suggested that the expression patterns of PfGyrA and
PfGyrB coincide with the time of DNA replication.
In order to investigate the expression of PfGyrA and PfGyrB
at the protein level, specific antibodies were raised against
purified antigens as shown in Fig. 2C. Anti-PfGyrA antibodies
were raised in mice, whereas anti-PfGyrB antibodies were
raised in rabbits. It has been shown previously that ACP is an
apicoplast-targeted protein (39, 52). ACP was purified as a
GST fusion protein, and polyclonal antibodies were raised
against the purified antigens in mice. To check the specificities
of these antibodies, Western blot analysis was performed as
shown in Fig. 2C. It was found that these antibodies could
specifically detect only the antigens against which they were
generated without showing any cross-reactivity with other an-
tigens (Fig. 2C). Other anti-PfGyrA and anti-PfGyrB antisera
were used for Western blot analysis using parasite lysates ob-
tained from late trophozoite/early schizont stages. The theo-
retical molecular masses of PfGyrA and PfGyrB are 143 kDa
and 116 kDa, respectively. Both antibodies recognized pre-
dominantly a single band close to their deduced molecular
masses (Fig. 2D). Preimmune sera under the same experimen-
tal conditions failed to recognize any such band, suggesting
that these proteins are truly expressed in the parasites.
Analysis of the amino-terminal sequences of both PfGyrA
and PfGyrB suggests the presence of an apicoplast-targeting
sequence comprising the transit peptide as well as the signal
peptide. In order to find out whether these proteins are truly
localized in the apicoplast, immunofluorescence experiments
were performed. Glass slides containing thin smears of the
parasites from different stages (as indicated in the figure leg-
ends) were prepared, and they were processed for the immu-
nofluorescence experiments. Initially, to determine the specific
location of the apicoplast, we performed immunofluorescence
assays using anti-GST-PfACP antibodies as a positive control.
We found a strong subnuclear green signal characteristic of the
apicoplast (Fig. 2E, panels 1 and 2). Preimmune sera under the
same experimental conditions did not show any signal (Fig. 2E,
panel 3). Following confirmation of the apicoplast localization
of PfACP, we performed colocalization experiments using a
mixture of anti-PfGyrB and anti-PfGyrA or anti-GST-PfACP
antibodies as described in Materials and Methods. Fluorescein
isothiocyanate-conjugated and Alexa red (Santa Cruz) second-
ary antibodies were used in these cases, and the green or red
fluorescence was monitored by using a NIKON fluorescence
microscope. Several hundred cells were scanned for cellular
localization as shown in Fig. 2E and F. The green fluorescence
and red fluorescence were detected in a subnuclear compart-
ment, and they merged reasonably well with each other (Fig.
2F). In the upper two panels of Fig. 2F, the signals of the
apicoplast-targeted protein ACP and PfGyrB overlapped with
each other, and in the lower two panels, PfGyrA and PfGyrB
signals merged with each other. Since ACP has previously been
shown to be specifically located at the apicoplast, these results
together suggest that PfGyrA and PfGyrB are localized in the
apicoplast. Preimmune sera under the same experimental con-
ditions do not show any signal that further confirms the spec-
ificity of these antibodies (data not shown).
P. falciparum gyrB complements an E. coli temperature-
sensitive strain. To further determine whether these putative
Pfgyr genes code for functional gyrase proteins, functional ge-
netic complementation in E. coli was performed (51). For this
purpose, E. coli gyrA temperature-sensitive mutant cells were
transformed with pAD1 containing the PfgyrA gene, and E. coli
gyrB temperature-sensitive mutant cells were transformed with
pAD2 containing the PfgyrB gene. pAD1 and pAD2 are the
derivatives of pHH3 and pAG111 containing EcgyrA and
against which they were raised without cross-reaction with other antigens. “M” indicates the molecular mass ladder. (D) 3D7 parasite pellets
enriched in late trophozoite/early schizont stages were boiled in SDS-PAGE loading buffer, and the supernatant was treated for SDS-PAGE
analysis followed by Western blot analysis using either anti-PfGyrA or anti-PfGyrB antibody (1:500 dilution) or the corresponding preimmune sera.
Molecular mass markers are shown on the right. (E) Localization of PfACP in the apicoplast. An immunofluorescence assay was performed using
anti-PfACP primary antibodies and fluorescein isothiocyanate (FITC)-conjugated secondary antibodies on glass slides containing thin smears of
nonsynchronized P. falciparum parasites as described in Materials and Methods. Panels 1 and 2 show that PfACP (green) is localized to the
apicoplast. No signal was obtained in panels where control preimmune serum was used. DAPI (4	,6	-diamidino-2-phenylindole) was used to stain
the nuclei. (F) Apicoplast localization of PfGyrA and PfGyrB. An immunofluorescence assay was performed using the above-described antibodies
on glass slides containing thin smears of P. falciparum parasites (mostly late trophozoite stages) as described in Materials and Methods. In panels
1and 2, PfACP (green) and PfGyrB (red) are colocalized to the apicoplast. In the third and fourth panels, PfGyrA (green) and PfGyrB (red) show
colocalization to the apicoplast. PfGyrB was probed with anti-PfGyrB antibody (rabbit, 1:500 dilutions), PfACP was probed with anti-PfACP
antibody (mouse, 1:1,000 dilutions), and PfGyrA was probed with anti-PfGyrA antibody (mouse, 1:500 dilution). In all cases, nuclei were
counterstained with DAPI.
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EcgyrB genes, respectively (26). We found that PfgyrA failed to
complement E. coli temperature-sensitive cells at the re-
strictive temperature, whereas PfGyrB could do that nicely
at the restrictive temperature (Fig. 3A and B, respectively).
E. coli gyrA and gyrB genes could rescue these temperature-
sensitive phenomena at the restrictive temperature nicely,
whereas the control, pBR322, could not rescue these phe-
notypes under the same experimental conditions. PfgyrA was
not expressed in the mutant E. coli strain even at 30°C
(nonrestrictive temperature), as anti-PfgyrA antibodies
failed to detect any band following Western blot analysis of
the lysate obtained from PfgyrA-transformed E. coli cells
(data not shown). However, PfgyrB was expressed nicely in
the E. coli gyrB mutant cells at both the normal temperature
and the restrictive temperature following Western blot anal-
ysis, as shown in Fig. 3C. These results suggest that PfgyrB is
a true gyrB homologue.
Analysis of intrinsic ATPase activity of PfGyrB (WT) and
other deletion mutants. In order to assess the ATPase activity
of PfGyrB and its stimulation in the presence of DNA or a
GyrA subunit, we performed an ATPase assay using either
wild-type or different deletion mutants of PfGyrB. We found
that full-length PfGyrB showed the maximum activity, followed
by PfGyrBN1, whereas PfGyrBN2 and PfGyrBC did not show
any activity (Fig. 4A). The ATPase domain of gyrase B is
confined to the N terminus domain that is included in the
deletion mutant N1. This result is similar to the recently pub-
lished report on the N-terminal ATPase domain of the P. vivax
GyrB subunit, which also shows in vitro ATPase activity (30).
These experiments also suggest that unlike EcGyrB, PfGyrB
shows strong intrinsic ATPase activity. In order to determine
whether the intrinsic ATPase activity of PfGyrB is not due to
the presence of any contaminant in the protein preparation, we
made a single point mutation at the conserved glutamic acid
(E159 to A) residue within the ATPase domain. The mutation
in the equivalent glutamic acid residue (E42) in EcGyrB com-
pletely eliminates the ATPase activity (29). The mutant pro-
tein did not show any ATPase activity compared with the wild
FIG. 3. Complementation analysis of E. coli temperature-sensitive strains KNK453 and N4177 with plasmids pAD1 and pAD2 carrying PfgyrA
and PfgyrB genes. (A) E. coli strain KNK453 was transformed with (i) pHH3, (ii) pBR322, or (iii) pAD1 containing PfgyrA. Bacterial cells were
plated onto LB agar plates and incubated at either a permissive temperature (30°C) or a nonpermissive temperature (43°C). (B) E. coli strain
N4177 was transformed with either (i) pAG111, (ii) pBR322, or (iii) pAD2 containing PfgyrB. Transformed bacteria were incubated at a permissive
temperature (30°C) or a nonpermissive temperature (42°C). (C) Detection of expression of PfGyrB in N4177 cells by immunoblotting using
anti-PfGyrB antibody. Lanes 1 and 3 contained extract from pAD2-transformed N4177 cells at permissive (30°C) and nonpermissive (42°C)
temperatures, while lane 2 contained extracts from the pBR322-transformed N4177 cells at a permissive (30°C) temperature.
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type, further confirming that the intrinsic ATPase activity of
PfGyrB is real (Fig. 4A).
One of the hallmarks of EcGyrB ATPase activity is its stim-
ulation in the presence of DNA and EcGyrA (33, 50). We
found that the addition of DNA or EcGyrA alone can stimu-
late the ATPase activity of PfGyrB to almost twice that of
PfGyrB alone (Fig. 4B). The addition of both DNA and
EcGyrA does not stimulate the ATPase activity significantly
FIG. 4. ATPase activity of P. falciparum gyrase B. In the cases of A and B, an ATPase assay was carried out in supercoiling buffer in the
presence of 1 mM cold ATP and 3.4 fmol [-32P]ATP, while in the cases of C, D, E, and G, the reactions were carried out by an NADH-coupled
enzymatic reaction (as described in Materials and Methods). (A) Comparison of the intrinsic ATPase activities of PfGyrB (WT), different deletion
mutants (as indicated), and a PfGyrB mutant [PfGyrB(mut)] with a point mutation as indicated in the inset, which shows the purification of
wild-type and mutant proteins. All the proteins were simultaneously purified and added to the reaction mixture in equimolar amounts (90 nM).
ATPase activity could be detected only in PfGyrB (WT) and PfGyrBN1. (B) Stimulation of the intrinsic ATPase activity of PfGyrB with EcGyrA
and DNA. The reactions were carried out in the presence of 90 nM PfGyrB (WT) and/or 90 nM EcGyrA and/or 10 g/ml linear pBR322 DNA
wherever applicable. (C) Effect of coumermycin on the ATPase activity of PfGyrB. Various concentrations of the drug coumermycin A1 (cou.) (0,
30, and 60 M) (as indicated in the figure with “■,” “Œ,” and “” symbols, respectively) were added at different substrate (ATP) concentrations
in the reaction mixture containing 200 nM PfGyrB enzyme, and ATP hydrolysis rates were measured. (D) Linear rate of ATP hydrolysis by PfGyrB
(WT) with ATP at a concentration of 2 mM and various amounts of enzymes. (E) Rate of ATP hydrolysis of PfGyrBN1 (43 kDa) with ATP at
a concentration of 2 mM with increasing amounts of enzymes. (F) Purification and Coomassie staining of PfGyrBN1 (PfGyrB43) and EcGyrB43
proteins. (G) Nonlinear rate of ATP hydrolysis of EcGyrB43 under the same experimental conditions as those for E. Each experiment was repeated
at least three times, and the results are quantitated and plotted graphically with error bars.
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compared to those of EcGyrA or DNA addition lanes (Fig. 4B).
EcGyrA does not show any activity, suggesting that PfGyrB is
able to form an active complex with an EcGyrA counterpart
that leads to the stimulation of ATPase activity. These results
together suggest that PfGyrB shows intrinsic ATPase activity
that can be stimulated in the presence of DNA or GyrA.
Coumermycin is a potent selective drug for bacterial gyrases
(50). In order to test the effect of this drug on PfGyrB (WT),
ATP hydrolysis rates were measured in the absence and pres-
ence of various drug concentrations. We found that increasing
concentrations of coumermycin could inhibit the rate of ATP
hydrolysis of PfGyrB in a dose-dependent manner (Fig. 4C). In
the absence of drug, PfGyrB (WT) ATPase activity shows
typical hyperbolic dependence on substrate concentration,
with a Km value of 1.05 mM (Fig. 4C; see Fig. S2 in the
supplemental material) that is comparable to the Km value
observed for the 43-kDa domain of E. coli GyrB (0.68 mM) (1).
The addition of coumermycin inhibited PfGyrB (WT) enzyme-
catalyzed ATP hydrolysis with a Ki value of 40 M (see Fig.
S2 in the supplemental material). This value is 500 times
higher than the Ki of EcGyrB (80 nM) (48) and 28-fold
higher than the Ki value of the 45-kDa P. vivax GyrB ATPase
domain (1.4 M) (30).
The rate of ATP hydrolysis with increasing full-length PfGyrB
(WT) enzyme concentrations was monitored (Fig. 4D). The
ATP hydrolysis rate was found to be linear with increasing
enzyme concentrations under our experimental conditions.
However, due to the low yield of PfGyrB (WT) enzyme, the
ATP hydrolysis rate could not be monitored at higher enzyme
concentrations. In order to circumvent this problem, the ATP
hydrolysis rate was calculated using increasing amounts of
PfGyrBN1 (43 kDa) (Fig. 4E), which gave us better yields and
showed ATPase activity (Fig. 4A). The ATP hydrolysis rates of
PfGyrBN1 (Fig. 4E) and the equivalent protein EcGyrB43
(Fig. 4G) were compared (purification of both the proteins is
shown in Fig. 4F). It was reported previously that EcGyrB43
shows a nonlinear pattern of ATP hydrolysis (1). We observed
that PfGyrBN1 followed a linear pattern of ATP hydrolysis
with increasing amounts of enzyme even at higher enzyme
concentrations under our experimental conditions (Fig. 4E).
Interestingly, the equivalent protein EcGyrB43 followed a
nonlinear pattern under the same experimental conditions, as
reported previously (Fig. 4G). Therefore, we conclude that
unlike EcGyrB, PfGyrB shows a linear pattern of ATP hydro-
lysis.
DNA cleavage and DNA supercoiling activity of PfGyrB in
combination with EcGyrA or PfGyrAN. The GyrA protein is
involved in the DNA breakage and reunion aspects of the
supercoiling reaction, whereas the GyrB protein is responsible
for ATP hydrolysis. The essential step in the DNA supercoiling
pathway is the cleavage of DNA in both strands. Ciprofloxacin,
a member of the quinolone family of drugs, interrupts the
cleavage and rejoining of the DNA strands. The addition of
SDS in such a trimeric reaction containing DNA, gyrase, and
drugs and the subsequent digestion of the protein lead to the
appearance of cleaved DNA. It has also been shown that the
addition of CaCl2 instead of MgCl2 in the gyrase reaction
mixture leads to a double-stranded DNA break at the same
site as those created by quinolone drugs. The N terminus of
EcGyrA, together with full-length EcGyrB, is sufficient to per-
form the DNA cleavage of supercoiled DNA (41).
We were interested to see whether the combination of
PfGyrAN and PfGyrB (WT) could lead to a functional complex
that can perform DNA cleavage and a supercoiling reaction.
For this purpose, we first performed a Ca2-directed DNA
cleavage reaction followed by the separation of these products
in an agarose gel, as described in Materials and Methods, by
using various combinations of E. coli and P. falciparum gyrase
enzymes. We found that PfGyrAN together with PfGyrB could
efficiently cleave supercoiled DNA that could be stabilized by
the use of Ca2 (Fig. 5A, lanes 4 and 5). The combination of
E. coli and P. falciparum gyrase subunits also stimulates the
DNA cleavage reaction in a Ca2-dependent manner (Fig. 5A,
lanes 2 and 3), compared to the control lane (lane 1). It was
also found that an active complex of PfGyrA and PfGyrB is
required for this reaction, since neither PfGyrA nor PfGyrB
alone could perform these reactions (Fig. 5A, lanes 6 and 7).
The intensities of the linear cleaved products (Fig. 5A) were
quantified using densitometry scanning, and the relative DNA
cleavage activities were plotted as shown in Fig. 5B.
It was shown previously that topoisomerase II inhibitors can
induce the cleavage of nuclear and apicoplast DNA in P. fal-
ciparum (55). To investigate whether a recombinant PfGyr
complex can perform a DNA cleavage reaction in the presence
ciprofloxacin, a series of experiments was performed in the
absence or presence of increasing amounts of ciprofloxacin
using either the E. coli or the P. falciparum gyrase enzyme
complex. The results shown in Fig. 5C indicate that both the
EcGyr and PfGyr complexes show DNA cleavage activity in
the presence of ciprofloxacin. Furthermore, PfGyr shows this
activity in a dose-dependent manner (Fig 5C, lanes 4 to 8). The
addition of EDTA in the reaction mixture following incubation
of the PfGyr complex in the presence of DNA and ciprofloxa-
cin resulted in the reversion of the DNA cleavage reaction
(Fig. 5C, lane 9), suggesting that the cleavage reaction is truly
performed by the PfGyr complex. Ciprofloxacin-mediated rel-
ative DNA cleavage activities are plotted in Fig. 5D. Together,
these results (Fig. 5A to D) suggest that PfGyrAN and PfGyrB
(WT) enzymes are functionally active.
Furthermore, to show whether the complex formed between
these two Plasmodium enzymes could perform a supercoiling
reaction, we checked their activities on relaxed DNA using
several combinations of E. coli and Plasmodium enzymes in the
presence of ATP. We observed that the gyrase complex com-
prising E. coli A and B subunits could transform relaxed DNA
into supercoiled DNA nicely, suggesting that our reaction con-
ditions are optimal for the supercoiling assay (Fig. 5E). PfGyrB
together with EcGyrA could also transform relaxed DNA into
supercoiled DNA in a dose-dependent manner to a very lim-
ited extent, suggesting that the ATPase activity of PfGyrB
could be used for the supercoiling reaction in combination with
EcGyrA in vitro (7, 46). The relatively poor activity of EcGyrA
and PfGyrB complexes in the supercoiling reaction could be
due to the fact that supercoiling is thermodynamically unfa-
vorable compared to other gyrase activities. The addition of
PfGyrAN in a reaction mixture containing PfGyrB did not lead
to the supercoiling of relaxed DNA (Fig. 5E), suggesting that
although PfGyrAN contained efficient DNA cleavage activity,
it might not retain all the functions required for DNA super-
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coiling activity. These results are also represented graphically
in Fig. 5F. In a control reaction, none of the gyrase subunits
alone can perform the supercoiling activity by themselves (data
not shown), suggesting that the combination of active gyrase A
and B subunits is required for supercoiling activity.
Dimerization of PfGyrB and PfGyrA subunits. The intrinsic
ATPase activity of PfGyrB and its linear rate of ATP hydrolysis
suggest that there are some differences in PfGyrB compared to
its E. coli counterpart. It was previously shown that E. coli
GyrB forms a dimer in the presence of a nonhydrolyzable
FIG. 5. DNA cleavage and supercoiling activity of P. falciparum gyrase. (A) CaCl2-induced DNA cleavage. Ten micrograms of supercoiled
pBR322 DNA per milliliter was incubated with 70 nM each PfGyrAN and EcGyrB (lane 2), 70 nM each EcGyrA and PfGyrB (lane 3), 70 nM each
PfGyrAN and PfGyrB (lane 4), 100 nM each PfGyrAN and PfGyrB (lane 5), 70 nM PfGyrAN alone (lane 6), or 70 nM PfGyrB alone (lane 7) in
a total reaction mixture volume of 30 l. Lane 1 does not contain any protein. The experimental procedure is discussed in Materials and Methods. 
and  indicate the presence or absence, respectively, of a particular protein in that reaction mixture. OC, open circular form of DNA; L, linear
form of DNA; S, supercoiled form of DNA. (B) Intensities of the linear bands following CaCl2-induced DNA cleavage reactions were quantitated
by densitometry scanning, and the values were plotted graphically. (C) Ciprofloxacin-induced DNA cleavage. The EcGyr or PfGyr complex (70 nM
each protein) was incubated for 1 h in the absence (lanes 2 and 4) or presence (lanes 3 and 5 to 8) of different concentrations of ciprofloxacin (Cip.)
(as indicated at the top), followed by SDS and proteinase K treatment and agarose gel electrophoresis of the reaction products as discussed in
Materials and Methods. Lane 1 did not contain any protein, and in lane 9, 10 mM EDTA was added before the addition of SDS and proteinase
K to show the reversibility of DNA cleavage reaction. (D) Intensities of the linear bands following ciprofloxacin-induced DNA cleavage reactions
were quantitated, and the values were plotted to obtain the relative DNA cleavage activity. (E) Supercoiling reaction of PfGyrB in combination
with EcGyrA and PfGyrAN. Ten micrograms of relaxed pBR322 DNA per milliliter was incubated in supercoiling buffer (see Materials and
Methods) with 70 nM EcGyrA in combination with 70 nM EcGyrB (lane2), 70 nM PfGyrB (lane3), 100 nM PfGyrB (lane 4), or 130 nM PfGyrB
(lane5). Lane 6 contains 100 nM each of PfGyrAN and PfGyrB. (F) The intensities of supercoiled DNA bands were quantified and are represented
by bar graphs.
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analogue of ATP (ADPNP) or competitive inhibitors of ATP
hydrolysis (coumermycin) that can account for the nonlinear
rate of ATP hydrolysis of this enzyme (1, 23, 47). We wanted
to verify whether this was true for PfGyrB. For this purpose, we
purified the N-terminal minimal region of PfGyrB (as shown in
Fig. 6A) and the equivalent counterpart, EcGyrB (containing
the conserved Ile128 residue that has been shown to be essen-
tial for the dimerization of EcGyrB). Glutaraldehyde cross-
linking experiments were performed in order to detect the
dimer forms of these proteins in the absence and presence of
coumermycin. We found that PfGyrBN2 could form strong and
stable dimers in the absence of the drug, as shown by glutar-
aldehyde cross-linking followed by Western blot analysis with
anti-His6 antibodies (Fig. 6B). On the contrary, only a fraction
of the EcGyrBN formed dimers in the presence of the drug
only. These results confirm the ATP-dependent dimerization
of EcGyrB as reported previously and also suggest that the
interfaces required for the ATP-independent dimerization of
PfGyrBN2 might be different.
To prove that the dimerization of His6-PfGyrBN2 is not due
to the addition of a His6 fusion tag, cross-linking experiments
using maltose binding protein (MBP)-tagged PfGyrBN2 in the
absence of ATP analogues were performed. Following West-
ern blot analysis using anti-MBP antibodies, cross-linked prod-
ucts (128 kDa) were obtained in the presence glutaraldehyde
for MBP-PfGyrBN2 only (Fig. 6C, lanes 1 and 2). MBP alone
did not yield any cross-linked product under the same exper-
imental conditions (Fig. 6C, lanes 3 and 4), suggesting that the
dimerization event is not the outcome of the inclusion of a
fusion tag. Finally, in order to evaluate the efficacy of dimer
formation of full-length PfGyrB (wild type) (103 kDa), cross-
linking experiments were performed using full-length His6-
PfGyrB (Fig. 6D). Western blot analysis using anti-His-tagged
polyclonal antibodies revealed dimer formation (206 kDa) in
the presence of glutaraldehyde and in the absence of ATP.
These results suggest that full-length PfGyrB has the poten-
tial to form dimers in the absence of ATP analogues like
PfGyrBN2.
In E. coli, the mutation of an isoleucine residue equivalent to
Ile128 in PfGyrB completely abrogates the ATP-dependent
dimerization (6). To test whether Ile128 plays a similar role in
the dimerization of PfGyrB, a point mutation was made in
PfGyrBN2 (Ile128 to Gly), and the mutant protein was sub-
jected to glutaraldehyde cross-linking followed by Western blot
analysis using anti-His antibodies (Fig. 6E and F). To our
surprise, the mutation in the Ile128 residue alone did not affect
dimer formation. These results suggest that residues other than
the Ile128 are important for the ATP-independent dimeriza-
tion of PfGyrB. Further detailed experiments are required to
find out the exact residues or region in PfGyrB that might
account for the dimer formation.
In order to rule out any possibility that the results of the
cross-linking experiments were due to technical artifacts,
PfGyrBN2 and PfGyrBN2M were subjected to native PAGE
analysis where both the proteins comigrated along with the
control, ovalbumin (43 kDa) (Fig. 6G). In the SDS-PAGE
analysis, His6-PfGyrBN2 showed an apparent molecular mass
of 22 kDa, which is very close to the molecular mass deduced
from the amino acid sequence (19 kDa) (Fig. 1F and 6B).
Therefore, the results obtained from native PAGE analysis
strongly suggest that PfGyrB forms a stable dimer in solution
in the absence of ATP and rule out any possibility of technical
artifacts in the cross-linking experiments.
Finally, we performed gel filtration chromatography using
either wild-type PfGyrB, PfGyrBN1, or PfGyrBN2 in the ab-
sence of ATP. These proteins were subjected to size-exclusion
chromatography using a Superose-12 gel filtration column,
which can be used to separate a broad range of proteins. The
column was first calibrated using different high- and low-mo-
lecular-mass gel filtration standards. Figure 6H shows the elu-
tion patterns of these standard proteins. Following calibration,
all the proteins (500 g each) described above were subjected
to chromatographic separation under the same experimental
conditions in the absence of ATP. Fractions were collected (0.5
ml each) and further analyzed by SDS-PAGE. The elution
patterns of these proteins are shown in Fig. 6H. The peak
fraction of wild-type PfGyrB (103 kDa) overlapped with the
peak fraction of a standard catalase that has a molecular mass
of 232 kDa, suggesting that wild-type PfGyrB is a dimer in
solution, as suggested by cross-linking experiments (Fig. 6D).
The peak fraction of PfGyrBN1 (43 kDa) eluted in fraction
29. The BSA standard eluted in fraction 30. These results
suggest that PfGyrBN1 in solution is possibly a dimer. The
elution pattern of PfGyBN2 (22 kDa) was little different.
One peak was observed around fraction 18. We think these are
multimeric forms of PfGyrBN2 or aggregation products of a
monomeric protein. However, there was another peak at frac-
tion 32 that coincides with the molecular mass standard of 43
kDa. We believe that these are dimeric forms of PfGyrB, as
suggested by the cross-linking experiments (Fig. 6A). Pres-
ently, we do not know the exact biophysical properties of the
high-molecular-weight fractions of PfGyrBN2. However, it is
clear that they will not enter the gel following cross-linking.
Very little protein coeluted in fraction 36, which is supposed to
be the position of the monomeric PfGyrBN2 (22 kDa) pro-
tein. These experiments together suggest that PfGyrB is mostly
a dimer in solution. Furthermore, the molecular masses of
these proteins were also deduced by plotting the log molecular
mass of the standards against the fraction numbers (see Fig. S3
in the supplemental material). The standard curve thus ob-
tained helped to deduce the apparent molecular masses of all
three proteins (as eluted by gel filtration chromatography),
which were very close to double the molecular mass of each
protein (PfGyrB [WT], 199.5 kDa; PfGyrBN1, 97.7 kDa;
PfGyrBN2, 39.8 kDa).
E. coli gyrase forms a heterotetrameric complex, A2B2, com-
prised of A and B subunits. However, each A and B subunit
forms dimers. It was previously shown that residues 363 to 494
are important for the dimerization of EcGyrA (13, 14). This
region does not show any homology with PfGyrA. However,
upon careful analysis of the PfGyrA sequence, we found a
unique leucine heptad repeat at the C terminus between res-
idues 835 and 856 (Fig. 6I). This region also shows a coiled-coil
domain as predicted by PAIRCOIL software. The BZIP type
of leucine zipper is often found in several transcription factors,
including jun and fos, that form dimers followed by DNA
binding (60). We were tempted to test whether this region in
PfGyrA forms a dimer. To test this, we purified His6-PfGyrCC
containing the leucine heptad repeat and performed glutaral-
dehyde cross-linking followed by Western blot analysis using
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FIG. 6. PfGyrB and PfGyrA are homodimers in solution. (A) Schematic diagram of the PfGyrBN2 ATPase domain containing the dimerization
interface. The conserved residue Ile128 is marked. (B) Comparison of the glutaraldehyde cross-linking products of PfGyrBN2 and EcGyrBN (1.0
M each) in the presence or absence of the drug coumermycin (Cou.) (0.5 M). “*” and “**” indicate the positions of the dimerized products
for PfGyrBN2 and EcGyrBN, respectively. (C) Glutaraldehyde cross-linking of MBP-tagged PfGyrBN2 (64 kDa) (lanes 1and 2) or MBP alone
(lanes 3 and 4). Experiments were carried out as described above (B), except for the Western blot analysis using anti-MBP polyclonal antibodies
and without the addition of ATP analogues. Arrows indicate the positions of the monomer, and the asterisk (*) indicates the position of the dimer
(128 kDa). (D) Cross-linking of His6-tagged full-length PfgyrB in the absence or presence of glutaraldehyde (lanes 1 and 2, respectively). The
arrow indicates the position of the monomer (103 kDa), and the asterisk (*) indicates the position of the dimer (206 kDa). (E) Purification
of PfGyrBN2 and PfGyrBN2M with a point mutation at Ile128. (F) Glutaraldehyde cross-linking status of the above-mentioned proteins.
(G) Native PAGE analysis of PfGyrBN2 and PfGyrBN2M. One microgram of each protein was loaded onto a 10% polyacrylamide native gel
followed by Coomassie staining. BSA (66 kDa), ovalbumin (43 kDa), and an NH2-terminal fragment of the P. falciparum ORC1 protein
(PfORC1N) (24 kDa) were also loaded as standards. The arrow indicates the position of both the wild-type and mutant proteins. (H) Size-exclusion
chromatography of wild-type PfGyrB, PfGyrBN2, and PfGyrBN1 in the absence of ATP. Wild-type or deletion mutant proteins were passed
through a Sepherose-12 gel filtration column, and 0.5-ml fractions were collected in each case. The fraction numbers are shown at the top. The
elution patterns of the following gel filtration standards are indicated at the top: thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa),
aldolase (158 kDa), bovine serum albumin (66 kDa), ovalbumin (43 kDa), and chymotrypsinogen (25 kDa). In each case, a 60-l sample was boiled
in SDS-PAGE boiling buffer followed by SDS-PAGE analysis and Coomassie staining of the gels to obtain the elution patterns of wild-type and
N-terminal deletion mutant proteins. Arrows facing upward indicate the positions of the peak fractions in each case. (I) Amino acid sequence of
leucine heptad repeats of PfGyrA from positions 835 to 856. (J) Glutaraldehyde cross-linking of PfGyrACC. One microgram of protein was
cross-linked with 0.001% glutaraldehyde in phosphate-buffered saline at 37°C for 15 min and subjected to SDS-PAGE followed by Western blot
analysis using anti-His6 polyclonal antibodies. BSA was also included in the reaction mixture as a control. PfGyrBC was used as a negative control
for the cross-linking reaction.
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anti-His6 polyclonal antibodies. We observed that PfGyACC
formed dimers as well as multimers, as shown in Fig. 6J. This
dimerization is specific, since the addition of BSA does not
change the nature of the cross-linked products, and a control
protein, PfGyrBC, without leucine heptad repeats does not
form dimers under the same experimental conditions. These
results suggest that the unique leucine heptad repeats might be
essential for the dimerization of PfGyrA.
DISCUSSION
The presence of both subunits of gyrase in the P. falciparum
genome, the inhibition of apicoplast DNA replication by cip-
rofloxacin, and the recent report of the characterization of the
ATPase domain of P. vivax gyrase B provide circumstantial
evidence for the presence of a functional gyrase in Plasmodium
(10, 30, 55). Interestingly, other than prokaryotes, functional
gyrase has been reported only in the plant Arabidopsis thaliana
(51). Studies of P. falciparum gyrases that are potentially good
targets for drugs have been limited due to the high AT content
and differential codon usage of Plasmodium. Here, we report
for the first time the cloning and functional biochemical char-
acterization of PfGyr subunits that are targeted to the apico-
plast.
As discussed above, the difficulties in the expression and
purification of large Plasmodium falciparum proteins in the
heterologous system might explain why there is no report in the
literature regarding the expression and purification of 100-
kDa P. falciparum proteins under normal conditions. Using
several optimization/standardization procedures, we have been
able to express and purify full-length PfGyrB as well as differ-
ent functional domains of PfGyrA. We found that the incuba-
tion of bacterial cultures at lower temperatures (20 to 22.5°C),
induction using low IPTG concentrations, and the use of the
specialized E. coli strain BL21 Codon Plus, which can supply
some of the rare codons (Arg, Ile, and Leu), might help to
express high-molecular-mass Plasmodium proteins in E. coli.
Interestingly, although we could express and purify the full-
length PfGyrB protein, we were unable to express the full-
length PfGyrA protein under the same experimental condi-
tions. However, we could express and purify two functional
domains of PfGyrA, and both domains were enzymatically
active, suggesting that the purification of full-length PfGyrA is
possible upon further optimization of the protocols.
RT-PCR analysis showed that the expression levels of
PfGyrA and PfGyrB transcripts peak during the trophozoite
and schizont stages. It was previously shown that apicoplast
DNA replication coincides with nuclear DNA replication and
that most of the DNA replication takes place during the late
trophozoite and schizont stages. Therefore, the expression pat-
terns of PfGyr subunits perfectly coincide with asexual DNA
replication stages.
In Plasmodium, the gyrases are encoded in the nucleus and
then carried to the apicoplast. Targeting of the gyrases to this
organelle is consistent with the absence of any DNA replica-
tion gene found in the apicoplast genome. In Arabidopsis,
separate GyrB proteins are targeted to the different organelles,
like the chloroplast and mitochondria. A. thaliana GyrA has a
dual translational initiation site targeting the mature protein to
both the chloroplast and mitochondria (51). The genome of
Plasmodium falciparum contains only one copy each of the
gyrA and gyrB genes. It would be interesting to see whether
these genes are targeted to mitochondria that contain 6-kb
linear DNA (11).
PfgyrB complemented E. coli gyrB temperature-sensitive mu-
tant cells at the restrictive temperature, whereas PfgyrA failed
to complement an E. coli gyrA temperature-sensitive strain.
Later, we found that PfgyrA was not expressed from plasmid
pAD1, which was used to transform E. coli gyrA temperature-
sensitive cells. The PfGyrA open reading frame did not contain
any mutation, suggesting that the inability to express PfgyrA in
a heterologous system could be attributed to the inherent
property of the gene. It is possible that some posttranslational
modification of PfGyrA is required for its stability.
We observed intrinsic ATPase activity of full-length PfGyrB.
The ATPase activity could be stimulated by the addition of
EcGyrA or DNA that is the hallmark of the ATPase activity of
gyrase. Significant ATPase activity has not been reported in the
case of E. coli gyrase B, except for one study that reported
appreciable intrinsic ATPase activity that was not stimulated
by E. coli GyrA and/or DNA. Mycobacterium smegmatis GyrB
also does not show intrinsic ATPase activity (31, 48). Those
results suggest that PfGyrB is different from its E. coli coun-
terpart.
Finally, in order to further investigate the differences in the
ATPase activities of the E. coli and P. falciparum counterparts,
we studied the rate of ATP hydrolysis with increasing full-
length enzyme concentrations. With increasing enzyme con-
centrations, the ATP hydrolysis curve follows a linear pattern
that is contrary to that of the E. coli enzyme, which follows a
nonlinear curve of ATP hydrolysis (Fig. 4E and G). A com-
parison of the ATPase activities of 43-kDa fragments of
PfGyrB and EcGyrB further confirmed the linear rate of ATP
hydrolysis in the case of PfGyrBN1 at higher enzyme concen-
trations. These results suggest that the enzyme kinetics of
PfGyrB are truly different from those of its E. coli counterpart.
The activation of monomeric EcGyrB needs ATP-depen-
dent dimerization, which accounts for the nonlinear rate of
ATP hydrolysis with respect to the enzyme concentration. One
obvious explanation for the apparent linear rate of ATP hy-
drolysis of PfGyrB is that dimerization is not necessary for
ATP hydrolysis for PfGyrB. Alternatively, it is possible that
PfGyrB exists as a stable dimer. The glutaraldehyde cross-
linking experiments, native PAGE analysis, and gel filtration
chromatography results confirm the latter hypothesis, since
PfGyrB forms a stable dimer in the absence of ATP, whereas
EcGyrB forms such dimers only in the presence of the ATP
analogue drug coumermycin.
The dimerization of PfGyrB was not restricted to any single
fragment. All fragments, including the full-length enzyme,
showed dimers to be the preferred state in solution both by
cross-linking experiments and by gel filtration chromatography
in the absence of ATP. It is not very surprising that PfGyrBN2
eluted as dimers and also as high-molecular-mass forms, al-
though PfGyrB (WT) and PfGyrBN1 eluted mostly as dimers
only. Due to the smaller size of PfGyrBN2, this protein is
always expressed in large quantities, and the yield is at least 5
to 10 times higher than those of the other forms of the pro-
teins. It is possible that the very high level of expression of the
proteins may push it to form higher-molecular-mass multi-
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meric or aggregated forms of the protein. However, there is a
definite pool of dimeric proteins, as shown in Fig. 6H.
These results for PfGyrB can be correlated to the ATP
hydrolysis studies of Saccharomyces cerevisiae topoisomerase
II. It was previously reported that the N terminus of yeast
topoisomerase II (1 to 409 residues) without the dimerization
domain shows a weak and nonlinear pattern of ATP hydrolysis,
whereas a larger fragment including the dimerization domain
(1 to 660 residues) shows a robust and linear pattern of ATP
hydrolysis (36). Interestingly, the mutation of the Ile128 resi-
due does not affect PfGyrB dimerization as it does for EcGyrB,
suggesting that other amino acid residues are important for
PfGyrB dimerization (6). Presently, we are trying to crystallize
PfGyrBN2, which might shed some light on these ideas. Fi-
nally, the identification of unique leucine heptad repeats in
PfGyrA leading to the dimerization/multimerization of this
region is also a novel finding. The functional implication of this
region in protein-protein or protein-DNA interactions needs
to be explored further.
These results also raise an important question: if PfgyrB can
dimerize in the absence of ATP, how can DNA segments (G or
T segment) enter the gyrase active site if the N gate remains
closed, as proposed by the model described previously by
Wang based on the findings on yeast topoisomerase II (53)?
Note that although the ATP-independent dimerization and
linear rate of the ATP hydrolysis pattern of PfGyrB are unique
for a gyrase enzyme, a similar result has been shown recently
for the Leishmania topoisomerase II enzyme, where the “N”-
terminal 43-kDa fragment shows ATP-independent dimeriza-
tion and a linear pattern of the ATP hydrolysis rate, like
PfGyrB (45). Together, these results suggest that these para-
sitic topoisomerase enzymes might have evolved in a different
way, which needs to be studied in great detail to understand
how the conventional model of the topoisomerase II “N” gate,
which opens and closes in an ATP-dependent manner, can be
extended to these unique systems. It is possible that these
enzymes follow a unique mechanism, which is a broader issue
and needs to be elucidated further.
The functional characterization of PfGyrB and the different
functional domains of PfGyrA set the platform for a detailed
biochemical and in vivo analysis of these enzymes, which are
good targets for therapy. The results presented in this study
lead to a simple model where two monomers of PfGyrB have
the propensity to form stable dimers in solution due to the
as-yet-unidentified dimer-forming interfaces (see Fig. S4 in the
supplemental material). These dimers show a linear rate of
ATP hydrolysis; the energy thus obtained can be used for DNA
cleavage and DNA supercoiling activity together with PfGyrA.
These data support the existence of a gyrase in the apicoplast
of P. falciparum. It is likely that the apicoplast has retained
a bacterium-type mechanism of DNA replication that re-
quires gyrase for the maintenance of supercoiling in the
organellar DNA.
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